ASP Isotopes (NASDAQ:ASPI) CEO Sells $691,578.28 in Stock

Key Points

• ASP Isotopes CEO Paul Elliot Mann sold 81,076 shares for $691,578.28, reducing his stake by 1.11% but still holds over 7 million shares valued at approximately $61.7 million.
• The company's stock is currently down 1.5%, trading at $8.37, with a year low of $2.32 and a year high of $11.68.
• ASP Isotopes recently reported a quarterly loss of ($1.03) earnings per share, significantly missing analyst expectations, and had revenue of $1.20 million compared to a forecast of $1.60 million.

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) CEO Paul Elliot Mann sold 81,076 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $8.53, for a total transaction of $691,578.28. Following the sale, the chief executive officer owned 7,234,378 shares of the company's stock, valued at approximately $61,709,244.34. The trade was a 1.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Paul Elliot Mann also recently made the following trade(s):

• On Tuesday, September 9th, Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock. The stock was sold at an average price of $8.39, for a total value of $680,236.03.

ASP Isotopes Stock Down 1.5%

ASPI traded down $0.13 during midday trading on Wednesday, reaching $8.37. The company's stock had a trading volume of 1,946,388 shares, compared to its average volume of 4,836,301. The stock's 50-day moving average is $9.08 and its 200-day moving average is $7.09. ASP Isotopes Inc. has a 1 year low of $2.32 and a 1 year high of $11.68. The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53. The firm has a market capitalization of $769.29 million, a price-to-earnings ratio of -13.72 and a beta of 3.35.

ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The business had revenue of $1.20 million during the quarter, compared to the consensus estimate of $1.60 million. ASP Isotopes had a negative return on equity of 239.22% and a negative net margin of 2,181.62%. As a group, research analysts expect that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group upped their price objective on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $7.75.

Hedge Funds Weigh In On ASP Isotopes

Several institutional investors and hedge funds have recently made changes to their positions in the business. AWM Investment Company Inc. increased its position in ASP Isotopes by 6.2% in the first quarter. AWM Investment Company Inc. now owns 4,511,186 shares of the company's stock worth $21,157,000 after buying an additional 265,000 shares during the period. Philadelphia Financial Management of San Francisco LLC boosted its stake in ASP Isotopes by 11.2% in the 1st quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company's stock valued at $16,453,000 after buying an additional 354,517 shares in the last quarter. Rovida Investment Management Ltd raised its position in ASP Isotopes by 528.6% in the 2nd quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock valued at $16,148,000 after purchasing an additional 1,850,000 shares during the last quarter. Rovida Advisors Inc. bought a new stake in shares of ASP Isotopes during the second quarter worth $16,148,000. Finally, Geode Capital Management LLC raised its position in shares of ASP Isotopes by 7.6% during the second quarter. Geode Capital Management LLC now owns 1,348,072 shares of the company's stock worth $9,924,000 after purchasing an additional 94,751 shares during the period. 16.80% of the stock is currently owned by hedge funds and other institutional investors.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.